Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 9/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.30 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
| ▸ | F9 | P00740 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20179384 | 0.95 | PDK2 (0.33) | PDK2MEN1KMT2A | |
| SCHEMBL20174523 | 0.95 | PDK2 (0.39) | PDK2MEN1KMT2AROCK1ALOX5 | |
| SCHEMBL20174451 | 0.93 | MEN1 (0.34) | PDK2MEN1KMT2AROCK1CA12 | |
| SCHEMBL20174444 | 0.93 | PDK2 (0.36) | PDK2ROCK1F9ALOX5 | |
| SCHEMBL20174506 | 0.91 | CYP1A1 (0.37) | PDK2ROCK1 | |
| SCHEMBL20174453 | 0.91 | MEN1 (0.33) | PDK2MEN1KMT2A | |
| SCHEMBL20174472 | 0.90 | PDK2 (0.37) | PDK2MEN1KMT2AROCK1F9 | |
| SCHEMBL20174469 | 0.90 | PDK2 (0.37) | PDK2MEN1KMT2AROCK1F9 | |
| SCHEMBL20174449 | 0.90 | PDK2 (0.37) | PDK2MEN1KMT2AROCK1F9 | |
| SCHEMBL20174466 | 0.88 | ALDH1A1 (0.33) | PDK2MEN1KMT2AENPP3ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738034-B2 | Spiro compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2020-08-11 | — | — | US | disclosed |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738034-B2 | Spiro compound and organic light-emitting device comprising same | CRY1, NR2E3, ERG | PDK2 651/4885MEN1 611/4885KMT2A 1480/4885 |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, NR2E3, ERG | PDK2 651/4885MEN1 611/4885KMT2A 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.